A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Eisai Inc.
PMV Pharmaceuticals, Inc
Mayo Clinic
Qilu Pharmaceutical Co., Ltd.
STORM Therapeutics LTD
Genmab
AstraZeneca
Genmab
AstraZeneca
Arvinas Inc.
DualityBio Inc.
Beijing Tide Pharmaceutical Co., Ltd
Radiopharm Theranostics, Ltd
Second Life Therapeutics
Tanabe Pharma America, Inc.
GV20 Therapeutics
Alaunos Therapeutics
Eli Lilly and Company
LigaChem Biosciences, Inc.
Bolt Biotherapeutics, Inc.
Incyte Corporation
Cancer Research UK
NuCana plc
PharmaMar
Marengo Therapeutics, Inc.
ModeX Therapeutics, An OPKO Health Company
Klus Pharma Inc.
Novartis
Aminex Therapeutics, Inc.
NextCure, Inc.
Innolake Biopharm
NextCure, Inc.
Western Sydney Local Health District
Incyte Corporation
Incyte Corporation
Gilead Sciences
NKGen Biotech, Inc.
Seagen Inc.
Petra Pharma
National Cancer Institute (NCI)